Komori
Sysmex (6869) · TargetShortfall against the previous medium-term plan's final-year targets and update to a new medium-term planLatest Governance (2026-10-01): "Advanced"

Achievement of ¥300 billion in consolidated net sales and ¥63 billion in operating profit

First written in FY2016. 4 of 13 entries say "Raised", first in FY2017. Latest entry: 2026-10-01.

13entries
11years
4from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRaisedFY2017 – FY2021OtherFY20242016: 120162017: 120172018: 120182019: 020192020: 120202021: 120212022: 120222023: 120232024: 120242025: 020252026: 52026
Same theme, other companies
Setting and Achieving Earnings Targets Under the Medium-Term Management PlanA theme 786 companies write about · 73 as a headwind · 1057 as a tailwind

The whole theme swung hardest in 2021: 17 of 77 companies on the "Worse" side.

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 133 companies compared. The sentences above are computed from all 133.Comparing 200 of the theme's 1175 threads.
Full recordFilings, disclosures and news, newest first
  1. 2026-10-01AdvancedGovernance

    「Our financial targets include revenue of at least ¥600,000 million, an operating margin of at least 16.7%, up 6.3 percentage points from fiscal 2025, and ROE of at least 12.0%, up 4.7 percentage points, as well as targets for capital efficiency, cash efficiency measured by CCC and cash-generation capacity.」

    The quantitative targets for revenue and operating margin, among others, under the new medium-term management plan for fiscal 2028 were recorded as specific progress in the thread concerning existing medium- to long-term growth targets. The canonical thread itself remains unchanged.
  2. FY2026Shortfall against the previous medium-term plan's final-year targets and update to a new medium-term planAnnual report

    「The Group launched a new medium-term management plan in April 2026, covering the three fiscal years from the fiscal year ending March 2027 through the fiscal year ending March 2029. It has established priority actions to undertake over the next 3 years and is promoting the execution of specific measures. Under the new medium-term management plan, it aims to achieve consolidated net sales of ¥600 billion and consolidated operating income of ¥100 billion in the fiscal year ending March 2029, the plan's final year.」

    Against the previous targets for the fiscal year ending March 2026 of net sales of ¥560 billion and operating income of ¥112 billion, actual results were net sales of ¥500.006 billion and operating income of ¥51.831 billion. Under the new plan, the final year has changed to the fiscal year ending March 2029, with targets of net sales of ¥600 billion and operating income of ¥100 billion.
  3. FY2024Update on performance against the previous medium-term plan and targets under the new medium-term planAnnual report

    「Under the previous medium-term management plan, the Group aimed to achieve consolidated net sales of ¥420 billion and consolidated operating income of ¥80 billion in the fiscal year ending March 2024, the plan's final year. As a result, net sales for the current consolidated fiscal year increased and exceeded plan, while operating income increased despite falling short of plan. Meanwhile, the Group launched a new medium-term management plan in April 2023, with the fiscal year ending March 2026 as its final year. It will continue to address important issues toward achieving its long-term vision, “Together, for a better healthcare journey,” and aims to achieve its management targets for the fiscal year ending March 2026: consolidated net sales of ¥560 billion and consolidated operating income of ¥112 billion.」

    The company disclosed that, under the previous medium-term plan, net sales for the fiscal year ending March 2024 exceeded plan, while operating income increased despite falling short of plan. The targets for the fiscal year ending March 2026, of net sales of ¥560 billion and operating income of ¥112 billion, remain unchanged.
  4. FY2023RaisedAnnual report

    「Meanwhile, the Group launched a new medium-term management plan in April 2023, with the fiscal year ending March 2026 as its final year. It will continue to address important issues toward achieving its long-term vision, “Together, for a better healthcare journey,” and aims to achieve its management targets for the fiscal year ending March 2026: consolidated net sales of ¥560 billion and consolidated operating income of ¥112 billion.」

    The final year has changed from the previous plan's fiscal year ending March 2024, with net sales of ¥420 billion and operating income of ¥80 billion, to the fiscal year ending March 2026, with new targets of net sales of ¥560 billion and operating income of ¥112 billion. The company states that, although results for the fiscal year ending March 2023 fell short of the previous plan's targets, both net sales and operating income increased year on year.
  5. FY2022Disclosure of the shortfall against the previous medium-term plan's final-year targetsAnnual report

    「Under the previous medium-term management plan, the Group aimed to achieve consolidated net sales of ¥380 billion and consolidated operating income of ¥78 billion in the fiscal year ending March 2022, the plan's final year. As a result, net sales and operating income for the current consolidated fiscal year both increased year on year, although they fell short of plan. Meanwhile, the Group launched a new medium-term management plan in April 2021, with the fiscal year ending March 2024 as its final year. It will continue to address important issues toward achieving its positioning targets based on its long-term vision and aims to achieve its management targets for the fiscal year ending March 2024: consolidated net sales of ¥420 billion and consolidated operating income of ¥80 billion.」

    The previous medium-term plan, whose final year was the fiscal year ending March 2022, targeted net sales of ¥380 billion and operating income of ¥78 billion, and the company disclosed that both fell short of plan. Meanwhile, the new targets for the fiscal year ending March 2024, of net sales of ¥420 billion and operating income of ¥80 billion, remain unchanged.
  6. FY2021RaisedAnnual report

    「Under the Group's medium-term management plan, we aim to achieve consolidated net sales of ¥420 billion and consolidated operating income of ¥80 billion in the fiscal year ending March 2024, the plan's final year.」

    The final year has changed from the fiscal year ending March 2022, with net sales of ¥380 billion and operating income of ¥78 billion, to the fiscal year ending March 2024, with targets of net sales of ¥420 billion and operating income of ¥80 billion. The performance forecast for the fiscal year ending March 2022 is net sales of ¥350 billion and operating income of ¥60 billion.
  7. FY2020RaisedAnnual report

    「Under the Group's medium-term management plan, we aim to achieve consolidated net sales of ¥380 billion and consolidated operating income of ¥78 billion in the fiscal year ending March 2022, the plan's final year.」

    The final year of the medium-term management plan has changed to the fiscal year ending March 2022, and the targets have been raised from net sales of ¥350 billion and operating income of ¥72 billion to net sales of ¥380 billion and operating income of ¥78 billion. Meanwhile, the annual targets for the fiscal year ending March 2020 were net sales of ¥310 billion and operating income of ¥60 billion, and the company states that both net sales and operating income fell short of plan.
  8. FY2018AdvancedAnnual report

    「The Group aims, under its medium-term management plan, to achieve consolidated net sales of ¥350 billion and consolidated operating income of ¥72 billion in the fiscal year ending March 2020, the plan's final year. Its targets for the fiscal year ending March 2018 were consolidated net sales of ¥280 billion and consolidated operating income of ¥58 billion. Both net sales and operating income for the current consolidated fiscal year exceeded the targets for the fiscal year ending March 2018, and we believe the Group is progressing steadily toward achieving the medium-term management plan.」

    The company states that it has maintained the medium-term management plan targets for the fiscal year ending March 2020 while achieving both interim targets for the fiscal year ending March 2018: net sales of ¥280 billion and operating income of ¥58 billion.
  9. FY2017RaisedAnnual report

    「Under the Group's medium-term management plan, we aim to achieve consolidated net sales of ¥350 billion and consolidated operating income of ¥72 billion in the fiscal year ending March 2020, the plan's final year.」

    The final year has changed from the fiscal year ending March 2018, with net sales of ¥300 billion and operating income of ¥63 billion, to the fiscal year ending March 2020, and the targets have been raised to net sales of ¥350 billion and operating income of ¥72 billion.
  10. FY2016First statedAnnual report

    「Under the Group's medium-term management plan, we aim to achieve consolidated net sales of ¥300 billion and consolidated operating income of ¥63 billion in the fiscal year ending March 2018, the plan's final year.」

    The consolidated performance targets for the fiscal year ending March 2018 are explicitly stated.
Moved together

"Strengthening the Group’s Management Platform Through Global Talent and ICT" moved the same way as this thread, in the same document, in 4 of its 13 moves.

443332★123456
  1. ★This thread
  2. 1Strengthening the Group’s Management Platform Through Global Talent and ICT4×
  3. 2Expansion of Global Sales and Service Infrastructure and Solution Proposals4×
  4. 3Multi-supplier procurement and disaster preparedness and recovery measures at manufacturing sites3×
  5. 4Expansion of the Genetic Testing Business Using Proprietary Technology3×
  6. 5Expansion of the Product Lineup in Hematology, Coagulation and Urinalysis3×
  7. 6ICT Risk Mitigation through Network Redundancy and Access Controls2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Sysmex yet. It last moved in the Governance of 2026-10-01: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Achievement of ¥300 billion in consolidated net sales and ¥63 billion in operating profit | SYSMEX CORPORATION (6869) | Komori